Log in

REDHILL BIOPHAR/S Stock Forecast, Price & News

+0.03 (+0.28 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $10.56
50-Day Range
MA: $8.41
52-Week Range
Now: $10.56
Volume242,137 shs
Average Volume380,894 shs
Market Capitalization$372.45 million
P/E RatioN/A
Dividend YieldN/A
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. It is also developing YELIVA that is in Phase IIa clinical trial for the treatment of advanced unresectable cholangiocarcinoma; is in Phase Ib/II clinical trial for refractory or relapsed multiple myeloma; and is in Phase II clinical trial for the treatment of advanced hepatocellular carcinoma. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RDHL



Sales & Book Value

Annual Sales$6.29 million
Book Value$2.74 per share


Net Income$-42,300,000.00
Net Margins-219.39%


Market Cap$372.45 million
Next Earnings Date11/17/2020 (Estimated)
+0.03 (+0.28 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions

How has REDHILL BIOPHAR/S's stock price been impacted by Coronavirus?

REDHILL BIOPHAR/S's stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RDHL shares have increased by 164.7% and is now trading at $10.56.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of REDHILL BIOPHAR/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for REDHILL BIOPHAR/S

When is REDHILL BIOPHAR/S's next earnings date?

REDHILL BIOPHAR/S is scheduled to release its next quarterly earnings announcement on Tuesday, November 17th 2020.
View our earnings forecast for REDHILL BIOPHAR/S

How were REDHILL BIOPHAR/S's earnings last quarter?

REDHILL BIOPHAR/S (NASDAQ:RDHL) released its quarterly earnings data on Thursday, August, 13th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.31. The biotechnology company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $20.52 million. REDHILL BIOPHAR/S had a negative net margin of 219.39% and a negative return on equity of 135.90%.
View REDHILL BIOPHAR/S's earnings history

What price target have analysts set for RDHL?

2 brokers have issued 12 month price objectives for REDHILL BIOPHAR/S's stock. Their forecasts range from $14.00 to $26.00. On average, they expect REDHILL BIOPHAR/S's stock price to reach $18.33 in the next year. This suggests a possible upside of 73.6% from the stock's current price.
View analysts' price targets for REDHILL BIOPHAR/S

Who are some of REDHILL BIOPHAR/S's key competitors?

What other stocks do shareholders of REDHILL BIOPHAR/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REDHILL BIOPHAR/S investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), NVIDIA (NVDA), Verastem (VSTM), Sangamo Therapeutics (SGMO), Tesla (TSLA), Inovio Pharmaceuticals (INO) and Gilead Sciences (GILD).

Who are REDHILL BIOPHAR/S's key executives?

REDHILL BIOPHAR/S's management team includes the following people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)
  • Mr. Gilead Raday, Chief Operating Officer (Age 44)
  • Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 49)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 43)

What is REDHILL BIOPHAR/S's stock symbol?

REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL."

Who are REDHILL BIOPHAR/S's major shareholders?

REDHILL BIOPHAR/S's stock is owned by many different retail and institutional investors. Top institutional investors include Ibex Investors LLC (5.30%), Creative Planning (2.22%), Gagnon Securities LLC (0.60%), Schonfeld Strategic Advisors LLC (0.28%), Phoenix Holdings Ltd. (0.28%) and Candriam Luxembourg S.C.A. (0.23%).

Which major investors are selling REDHILL BIOPHAR/S stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including CLARET ASSET MANAGEMENT Corp, and Schonfeld Strategic Advisors LLC.

Which major investors are buying REDHILL BIOPHAR/S stock?

RDHL stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning, Gagnon Securities LLC, California Public Employees Retirement System, Goldman Sachs Group Inc., Ibex Investors LLC, Phoenix Holdings Ltd., Candriam Luxembourg S.C.A., and Bank of New York Mellon Corp.

How do I buy shares of REDHILL BIOPHAR/S?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is REDHILL BIOPHAR/S's stock price today?

One share of RDHL stock can currently be purchased for approximately $10.56.

How big of a company is REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S has a market capitalization of $372.45 million and generates $6.29 million in revenue each year. The biotechnology company earns $-42,300,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. REDHILL BIOPHAR/S employs 75 workers across the globe.

What is REDHILL BIOPHAR/S's official website?

The official website for REDHILL BIOPHAR/S is www.redhillbio.com.

How can I contact REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.